Document is current
Any future updates will be listed below
-
Authors
Bassil, Christopher F. https://orcid.org/0000-0002-2692-8611
Dillon, Kerry
Anderson, Gray R.
Mayro, Benjamin
Askin, Kayleigh N.
Winter, Peter S.
Harry, Stefan
Gruber, Samuel
Hall, Tierney M.
Hoj, Jacob P. https://orcid.org/0000-0003-3298-3083
Cerda-Smith, Christian https://orcid.org/0000-0001-8123-5300
Hutchinson, Haley M. https://orcid.org/0000-0002-8181-6022
Killarney, Shane T. https://orcid.org/0000-0002-8471-6641
Heffernan, Ava
Teddy, Caroline
Singleton, Katherine R.
Qin, Li https://orcid.org/0000-0002-8476-3800
Jubien-Girard, Kévin
Favreau, Cécile
Robert, Guillaume https://orcid.org/0000-0002-6350-2222
Tivon, Barr
Livnah, Ella
London, Nir
Benhida, Rachid
Auberger, Patrick
Pendergast, Ann Marie
Bar-Peled, Liron https://orcid.org/0000-0003-2687-9546
Lonard, David M. https://orcid.org/0000-0002-4876-8479
Martin, Anthony R. https://orcid.org/0000-0001-6187-6979
Puissant, Alexandre https://orcid.org/0000-0002-3997-9282
Wood, Kris C. https://orcid.org/0000-0002-5887-2253
- License Information
-
More Information
Article History
Received: 14 January 2025
Accepted: 2 January 2026
First Online: 14 January 2026
Competing interests
: K.C.W. is a founder, consultant, and equity holder at Tavros Therapeutics and Celldom, an equity holder at Decrypt Bio and Simple Therapeutics, and has performed consulting work for Guidepoint Global, Bantam Pharmaceuticals, and Apple Tree Partners. D.M.L. is a paid consultant and holds an equity position in CoRegen, Inc., a biotechnology company developing MCB-613 for clinical use. The remaining authors declare no competing interests.
